Zhong-Zheng Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zhong-Zheng Zhu has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Ai-Zhong Wang
7 shared publicationsGuan-Shan Zhu
Innovation Center China, AstraZeneca Global R & D, Shanghai 201203, China
4 shared publicationsXiang-Lei He
Department of Pathology, Lihuili Hospital, Ningbo 315041, China
4 shared publicationsGuanshan Zhu
3 shared publicationsHang-Ruo Jia
Department of Pathology, No. 113 Hospital of People’s Liberation Army, Ningbo 315040, China
3 shared publications- Lifang Hou
Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
3 shared publications
Latest Publications
- Open Access
- 31 January 2012
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 13 (1) , 225-229
Sex-related Differences in DNA Copy Number Alterations in Hepatitis B Virus-Associated Hepatocellular Carcinoma
Males have a higher prevalence of hepatocellular carcinoma (HCC) than females in general, but the reasons for the sex disparity are still obscure. DNA copy number alteration (CNA) is a major feature of solid tumors including HCC, but whether CNA plays a role in sex-related differences in HCC development has never been evaluated. High-resolution array comparative genomic hybridization (CGH) was used to examine 17 female and 46 male HCC patients with chronic hepatitis B virus (HBV) infection in Shanghai, China. Two-tailed Fisher's exact or chi2 tests was used to compare CNAs between females and males. The overall frequencies and patterns of CNAs in female and male cases were similar. However, female HCC tumors presented more copy number gains compared to those in males on 1q21.3-q22 (76.5% vs. 37.0%, P = 0.009), 11q11 (35.3% vs. 0.0%, P = 0.0002) and 19q13.31-q13.32 (23.5% vs. 0.0%, P = 0.004), and loss on 16p11.2 (35.3% vs. 6.5%, P = 0.009). Relative to females, male cases had greater copy number loss on 11q11 (63.0% vs. 17.6%, P = 0.002). Further analyses showed that 11q11 gain correlated with 19q13.31-q13.32 gain (P = 0.042), 11q11 loss (P = 0.011) and 16p11.2 loss (P = 0.033), while 1q21.3-q22 gain correlated with 19q13.31-q13.32 gain (P = 0.046). These findings suggest that CNAs may play a role in sex-related differences in HBV-associated HCC development.
- 31 January 2012
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 13 (1) , 225-229
Open AccessSex-related Differences in DNA Copy Number Alterations in Hepatitis B Virus-Associated Hepatocellular Carcinoma
Males have a higher prevalence of hepatocellular carcinoma (HCC) than females in general, but the reasons for the sex disparity are still obscure. DNA copy number alteration (CNA) is a major feature of solid tumors including HCC, but whether CNA plays a role in sex-related differences in HCC development has never been evaluated. High-resolution array comparative genomic hybridization (CGH) was used to examine 17 female and 46 male HCC patients with chronic hepatitis B virus (HBV) infection in Shanghai, China. Two-tailed Fisher's exact or chi2 tests was used to compare CNAs between females and males. The overall frequencies and patterns of CNAs in female and male cases were similar. However, female HCC tumors presented more copy number gains compared to those in males on 1q21.3-q22 (76.5% vs. 37.0%, P = 0.009), 11q11 (35.3% vs. 0.0%, P = 0.0002) and 19q13.31-q13.32 (23.5% vs. 0.0%, P = 0.004), and loss on 16p11.2 (35.3% vs. 6.5%, P = 0.009). Relative to females, male cases had greater copy number loss on 11q11 (63.0% vs. 17.6%, P = 0.002). Further analyses showed that 11q11 gain correlated with 19q13.31-q13.32 gain (P = 0.042), 11q11 loss (P = 0.011) and 16p11.2 loss (P = 0.033), while 1q21.3-q22 gain correlated with 19q13.31-q13.32 gain (P = 0.046). These findings suggest that CNAs may play a role in sex-related differences in HBV-associated HCC development.
- 20 January 2012
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 32 (1) , 5-9
Sex-dependent differences in DNA copy number alterations in hepatocellular carcinoma
- 20 January 2012
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 32 (1) , 5-9
Sex-dependent differences in DNA copy number alterations in hepatocellular carcinoma
- 1 January 2011
- Vol. 12 (7) , 1771-6
Frequent germline mutation in the BRCA2 gene in esophageal squamous cell carcinoma patients from a low-risk Chinese population.
The incidence of esophageal squamous cell cancer (ESCC) is strikingly variable by geographic area, which reflect different exposures to risk factors, including genetic predisposition. Previous studies of ESCC patients from several high-risk populations suggested that BRCA2 might play a role in the etiology. This study was conducted to screen for mutations of BRCA2 gene in ESCC cases from a low-risk population. Forty-seven ESCC patients from a low-risk area of Southeast China were screened for mutations in the entire coding region of the BRCA2 gene by direct sequencing. No somatic mutations were observed in tumors. In total, 9 germline missense point mutations, each in one patient, were identified in male sporadic patients, with a mutation frequency of 19%. Of the 9 mutations, 7 were of heterozygous, while the remaining 2 were homozygous. Screening of an additional 94 healthy controls for the 9 mutations identified in ESCC cases showed that there was only 2 (2%) positive individuals, each carrying one of the mutations. Thus the mutation frequency in ESCC cases (19%) was significantly higher than that in healthy controls (OR = 10.9, 95% CI = 2.2-52.8, P = 0.003). No significant associations were observed for germline BRCA2 mutations with age, sex, cigarette smoking, alcohol drinking and family history of cancer. This series of cases from a low-risk Chinese population presented the highest frequency of germline BRCA2 mutations in ESCC reported to date, highlighting possible etiology roles in this population.
- 1 January 2011
- Vol. 12 (7) , 1771-6
Frequent germline mutation in the BRCA2 gene in esophageal squamous cell carcinoma patients from a low-risk Chinese population.
The incidence of esophageal squamous cell cancer (ESCC) is strikingly variable by geographic area, which reflect different exposures to risk factors, including genetic predisposition. Previous studies of ESCC patients from several high-risk populations suggested that BRCA2 might play a role in the etiology. This study was conducted to screen for mutations of BRCA2 gene in ESCC cases from a low-risk population. Forty-seven ESCC patients from a low-risk area of Southeast China were screened for mutations in the entire coding region of the BRCA2 gene by direct sequencing. No somatic mutations were observed in tumors. In total, 9 germline missense point mutations, each in one patient, were identified in male sporadic patients, with a mutation frequency of 19%. Of the 9 mutations, 7 were of heterozygous, while the remaining 2 were homozygous. Screening of an additional 94 healthy controls for the 9 mutations identified in ESCC cases showed that there was only 2 (2%) positive individuals, each carrying one of the mutations. Thus the mutation frequency in ESCC cases (19%) was significantly higher than that in healthy controls (OR = 10.9, 95% CI = 2.2-52.8, P = 0.003). No significant associations were observed for germline BRCA2 mutations with age, sex, cigarette smoking, alcohol drinking and family history of cancer. This series of cases from a low-risk Chinese population presented the highest frequency of germline BRCA2 mutations in ESCC reported to date, highlighting possible etiology roles in this population.
- Open Access
- 9 August 2010
- Published by Springer Nature in Environmental Health
- Vol. 9 (1) , 48
Airborne particulate matter and mitochondrial damage: a cross-sectional study
Oxidative stress generation is a primary mechanism mediating the effects of Particulate Matter (PM) on human health. Although mitochondria are both the major intracellular source and target of oxidative stress, the effect of PM on mitochondria has never been evaluated in exposed individuals.
- 9 August 2010
- Published by Springer Nature in Environmental Health
- Vol. 9 (1) , 48
Open AccessAirborne particulate matter and mitochondrial damage: a cross-sectional study
Oxidative stress generation is a primary mechanism mediating the effects of Particulate Matter (PM) on human health. Although mitochondria are both the major intracellular source and target of oxidative stress, the effect of PM on mitochondria has never been evaluated in exposed individuals.
- 1 November 2008
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 9 (11) , 847-852
Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression
To evaluate the association between p53 codon 72 polymorphism (R72P) and the risk of colorectal liver metastases. The p53 R72P genotype was identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 78 consecutive colorectal cancer patients with liver metastases and 214 age-and sex-matched cases with nonmetastatic colorectal cancer. The R allele of the p53 R72P polymorphism was more frequently found in metastatic cases than in nonmetastatic cases (P=0.075). Carriers of the 72R allele had a 2.25-fold (95% CI (confidence interval)= 1.05∼4.83) increased risk of liver metastases. On the stratification analysis, 72R-carrying genotype conferred a 3.46-fold (95% CI=1.02∼11.72) and a 1.05-fold (95% CI=0.36∼3.08) increased risk of liver metastases for p53 overexpression-positive and negative colorectal cancers, respectively. These results demonstrate for the first time that the 72R allele of the p53 polymorphism has an increased risk for liver metastases in colorectal cancers positive for p53 overexpression.
- 1 November 2008
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 9 (11) , 847-852
Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression
To evaluate the association between p53 codon 72 polymorphism (R72P) and the risk of colorectal liver metastases. The p53 R72P genotype was identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 78 consecutive colorectal cancer patients with liver metastases and 214 age-and sex-matched cases with nonmetastatic colorectal cancer. The R allele of the p53 R72P polymorphism was more frequently found in metastatic cases than in nonmetastatic cases (P=0.075). Carriers of the 72R allele had a 2.25-fold (95% CI (confidence interval)= 1.05∼4.83) increased risk of liver metastases. On the stratification analysis, 72R-carrying genotype conferred a 3.46-fold (95% CI=1.02∼11.72) and a 1.05-fold (95% CI=0.36∼3.08) increased risk of liver metastases for p53 overexpression-positive and negative colorectal cancers, respectively. These results demonstrate for the first time that the 72R allele of the p53 polymorphism has an increased risk for liver metastases in colorectal cancers positive for p53 overexpression.
- 1 September 2008
- Vol. 30 (9) , 702-5
[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
To evaluate the significance of a panel of immunohistochemical markers for distinguishing hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (ICC). Ten markers including hepatocyte paraffin 1 (Hep Par 1), polyclonal carcinoembryonic antigen (pCEA), CD34, CD10, CD105, multidrug resistance-associated protein-3 (MRP-3), cyclooxygenase-2 (COX-2), mucinous glycoprotein-1 (MUC-1), aquaporin-1 (AQP-1) and CK19 were immunohistochemically stained in the samples from 90 surgically resected HCC and 80 ICC, respectively,and the positive rate of their expression were compared statistically. The positive expression rates of Hep Par 1, pCEA, CD34, CD10, CD105, MRP-3, COX-2 were 85.6%, 82.2%, 87.8%, 18.9%, 8.9%, 11.1% and 48.9%, respectively, in HCC. While the positive expression rates of MUC-1, AQP-1 and CK19 were 73.8%, 65% and 92.5%, respectively, in ICC. Based on our results, Hep Par 1 and CD34 can be used as the first line markers, and pCEA and COX-2 as the second line makers, for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma. While MUC-1 and CK19 can be used as the first line markers and AQP-1 as the second one for the differential diagnosis of intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
- 1 September 2008
- Vol. 30 (9) , 702-5
[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
To evaluate the significance of a panel of immunohistochemical markers for distinguishing hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (ICC). Ten markers including hepatocyte paraffin 1 (Hep Par 1), polyclonal carcinoembryonic antigen (pCEA), CD34, CD10, CD105, multidrug resistance-associated protein-3 (MRP-3), cyclooxygenase-2 (COX-2), mucinous glycoprotein-1 (MUC-1), aquaporin-1 (AQP-1) and CK19 were immunohistochemically stained in the samples from 90 surgically resected HCC and 80 ICC, respectively,and the positive rate of their expression were compared statistically. The positive expression rates of Hep Par 1, pCEA, CD34, CD10, CD105, MRP-3, COX-2 were 85.6%, 82.2%, 87.8%, 18.9%, 8.9%, 11.1% and 48.9%, respectively, in HCC. While the positive expression rates of MUC-1, AQP-1 and CK19 were 73.8%, 65% and 92.5%, respectively, in ICC. Based on our results, Hep Par 1 and CD34 can be used as the first line markers, and pCEA and COX-2 as the second line makers, for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma. While MUC-1 and CK19 can be used as the first line markers and AQP-1 as the second one for the differential diagnosis of intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
- 1 April 2008
- Vol. 25 (2) , 168-71
[Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer].
To investigate the possible association between the single nucleotide polymorphisms (SNPs) (C-8343G, C-1863T and R72P) in TP53 gene and susceptibility to liver metastases of colorectal cancer (CRC) in a Chinese population. The genotypes of each SNP in TP53 gene were determined by either TaqMan assays or PCR-based restriction fragment length polymorphism (RFLP) method in 121 colorectal cancer patients with liver metastases and sex-, age-matched 280 cases with nonmetastatic CRC as a control. Immunohistochemical staining for P53 was performed on paraffin-embedded sections. Odds ratios (ORs) for colorectal liver metastases and 95% confidence intervals (CIs) from unconditional logistic regression models were used to evaluate relative risks. No significant association of C-8343G or C-1863T with colorectal liver metastases risk was observed. However, the R allele of the TP53 R72P polymorphism was more frequently found in metastatic cases than in nonmetastatic cases (P= 0.037). When compared with PP homozygotes, the ORs of metastases for RP heterozygotes was 2.21 (95% CI: 1.13-4.33), for RR homozygotes was 2.26 (95% CI: 1.03-4.94), and for carriers of the 72R allele (RP or RR genotype) was 2.22 (95% CI: 1.16-4.26). Stratified analysis indicated that carrying the 72R allele had a more pronounced increase in colorectal liver metastases risk among patients with positive P53 expression tumors (OR= 3.28, 95% CI: 1.21-8.88), whereas no significantly increased metastases risk was found in patients with negative P53 expression tumors (OR= 1.37, 95% CI: 0.52-3.62). The R allele of the TP53 R72P polymorphism may contribute to the etiology of liver metastases in CRC patients, particularly among those with positive P53 expression tumors. Both TP53 C-8343G and C-1863T may be not associated with colorectal liver metastases risk.
- 1 April 2008
- Vol. 25 (2) , 168-71
[Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer].
To investigate the possible association between the single nucleotide polymorphisms (SNPs) (C-8343G, C-1863T and R72P) in TP53 gene and susceptibility to liver metastases of colorectal cancer (CRC) in a Chinese population. The genotypes of each SNP in TP53 gene were determined by either TaqMan assays or PCR-based restriction fragment length polymorphism (RFLP) method in 121 colorectal cancer patients with liver metastases and sex-, age-matched 280 cases with nonmetastatic CRC as a control. Immunohistochemical staining for P53 was performed on paraffin-embedded sections. Odds ratios (ORs) for colorectal liver metastases and 95% confidence intervals (CIs) from unconditional logistic regression models were used to evaluate relative risks. No significant association of C-8343G or C-1863T with colorectal liver metastases risk was observed. However, the R allele of the TP53 R72P polymorphism was more frequently found in metastatic cases than in nonmetastatic cases (P= 0.037). When compared with PP homozygotes, the ORs of metastases for RP heterozygotes was 2.21 (95% CI: 1.13-4.33), for RR homozygotes was 2.26 (95% CI: 1.03-4.94), and for carriers of the 72R allele (RP or RR genotype) was 2.22 (95% CI: 1.16-4.26). Stratified analysis indicated that carrying the 72R allele had a more pronounced increase in colorectal liver metastases risk among patients with positive P53 expression tumors (OR= 3.28, 95% CI: 1.21-8.88), whereas no significantly increased metastases risk was found in patients with negative P53 expression tumors (OR= 1.37, 95% CI: 0.52-3.62). The R allele of the TP53 R72P polymorphism may contribute to the etiology of liver metastases in CRC patients, particularly among those with positive P53 expression tumors. Both TP53 C-8343G and C-1863T may be not associated with colorectal liver metastases risk.
- 25 January 2008
- Vol. 27, 4243-7
COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population.
Although a number of studies on the polymorphisms in COX1 and COX2 genes in association with risks for a number of cancers have been conducted, their relation to gastric cancer has not been well studied. Genotypes of several variants in both COX1 (Ex7+31 C>A and Ex10-4 G>A) and COX2 (-765 G>C, Ex10+837 T>C, Ex10-90 C>T, IVS5-275 T>G, and IVS7+111 T>C) were identified by TaqMan assays in 305 gastric cancer cases and 427 age- and gender-matched controls in a high-risk Polish population. Odds ratios for gastric cancer and 95% confidence intervals from unconditional logistic regression models were used to evaluate relative risks. We found no statistically significant evidence that the polymorphisms tested in COX1 and COX2 are associated with gastric cancer risk. These results suggest that the polymorphisms examined in COX1 and COX2 do not affect the risk of gastric cancer.
- 25 January 2008
- Vol. 27, 4243-7
COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population.
Although a number of studies on the polymorphisms in COX1 and COX2 genes in association with risks for a number of cancers have been conducted, their relation to gastric cancer has not been well studied. Genotypes of several variants in both COX1 (Ex7+31 C>A and Ex10-4 G>A) and COX2 (-765 G>C, Ex10+837 T>C, Ex10-90 C>T, IVS5-275 T>G, and IVS7+111 T>C) were identified by TaqMan assays in 305 gastric cancer cases and 427 age- and gender-matched controls in a high-risk Polish population. Odds ratios for gastric cancer and 95% confidence intervals from unconditional logistic regression models were used to evaluate relative risks. We found no statistically significant evidence that the polymorphisms tested in COX1 and COX2 are associated with gastric cancer risk. These results suggest that the polymorphisms examined in COX1 and COX2 do not affect the risk of gastric cancer.
- Open Access
- 1 January 2008
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 16 (35)
Transforming growth factor-beta 1 gene C-509T polymorphism and genetic susceptibility to colorectal cancer
目的: 探讨转化生长因子β1基因(TGF-β1)C-509T多态与结直肠癌(colorectal cancer, CRC)遗传易感性的关系. 方法: 采用TaqMan方法检测345例CRC与670名对照的TGF-β1 C-509T基因型分布及差异. 结果: CRC组与对照组T等位基因频率分别为43.5%、48.8%, T的CRC发病风险是C的0.82倍(95%CI 0.68-0.99, P = 0.037). 与CC纯合子相比, CT杂合子引起CRC风险为0.79倍(95%CI 0.58-1.08, P = 0.137), 而TT纯合子引起CRC风险显著降低至0.66倍(95%CI 0.45-0.96, P = 0.032). 将CT、TT基因型合并计算, 则其CRC发病风险与CC基因型相比降低至0.75倍(95%CI 0.56-1.00, P = 0.052). 结论: TGF-β1基因C-509T多态是中国人群重要的CRC遗传保护因子, 可作为CRC发病风险评估的筛选指标.
- 1 January 2008
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 16 (35)
Open AccessTransforming growth factor-beta 1 gene C-509T polymorphism and genetic susceptibility to colorectal cancer
目的: 探讨转化生长因子β1基因(TGF-β1)C-509T多态与结直肠癌(colorectal cancer, CRC)遗传易感性的关系. 方法: 采用TaqMan方法检测345例CRC与670名对照的TGF-β1 C-509T基因型分布及差异. 结果: CRC组与对照组T等位基因频率分别为43.5%、48.8%, T的CRC发病风险是C的0.82倍(95%CI 0.68-0.99, P = 0.037). 与CC纯合子相比, CT杂合子引起CRC风险为0.79倍(95%CI 0.58-1.08, P = 0.137), 而TT纯合子引起CRC风险显著降低至0.66倍(95%CI 0.45-0.96, P = 0.032). 将CT、TT基因型合并计算, 则其CRC发病风险与CC基因型相比降低至0.75倍(95%CI 0.56-1.00, P = 0.052). 结论: TGF-β1基因C-509T多态是中国人群重要的CRC遗传保护因子, 可作为CRC发病风险评估的筛选指标.
- 1 July 2007
- Vol. 35 (7) , 637-40
[The glutamate-cysteine ligase catalytic subunit gene C-129T and modifier subunit gene G-23T polymorphisms and risk for coronary diseases].
To investigate the possible association between the glutamate-cysteine ligase catalytic subunit gene (GCLC) C-129T and modifier subunit gene (GCLM) G-23T polymorphisms with coronary heart disease (CHD) in Chinese population. GCLC C-129T and GCLM G-23T genotypes were determined in 212 CHD patients and 218 healthy individuals using a PCR-based restriction fragment length polymorphism (RFLP) method. Odds ratio (OR) for CHD and 95% confidence interval (CI) from unconditional logistic regression models were used to evaluate relative risks. The T allele of the GCLC C-129T polymorphism was more frequently found in CHD cases than in controls (P < 0.01) and individuals with GCLC-129T allele had a significantly higher risk for CHD (OR = 2.38, 95% CI: 1.25 - 4.54) as compared to individuals with the -129C allele. When compared with CC homozygote, CT heterozygote had a 2.14-fold higher risk for CHD (95% CI: 1.08 - 4.24, P < 0.05) and carriers of the-129T allele (CT or TT genotype) also had a similarly 2.28-fold higher risk for CHD (95% CI: 1.16 - 4.49, P < 0.05). In contrast, the frequency of T allele of the GCLM G-23T polymorphism was lower in CHD patients than that of controls (0.174 vs. 0.264) and individuals with the GCLM-23T allele had a significantly lower risk for CHD (OR = 0.59, 95% CI: 0.42 - 0.82, P < 0.01) as compared to the -23G allele. When compared with GG homozygote, the OR of CHD for GT heterozygote was 0.71 (95% CI: 0.47 - 1.08, P > 0.05), for TT homozygote was 0.18 (95% CI: 0.06 - 0.55, P < 0.01), and for carriers of the -23T allele (GT or TT genotype) was 0.61 (95% CI: 0.42 - 0.92, P < 0.05). The GCLC C-129T polymorphism may be one of the genetic risk factor while the GCLM G-23T polymorphism may be one of the genetic protective factors for CHD in this Chinese population.
- 1 July 2007
- Vol. 35 (7) , 637-40
[The glutamate-cysteine ligase catalytic subunit gene C-129T and modifier subunit gene G-23T polymorphisms and risk for coronary diseases].
To investigate the possible association between the glutamate-cysteine ligase catalytic subunit gene (GCLC) C-129T and modifier subunit gene (GCLM) G-23T polymorphisms with coronary heart disease (CHD) in Chinese population. GCLC C-129T and GCLM G-23T genotypes were determined in 212 CHD patients and 218 healthy individuals using a PCR-based restriction fragment length polymorphism (RFLP) method. Odds ratio (OR) for CHD and 95% confidence interval (CI) from unconditional logistic regression models were used to evaluate relative risks. The T allele of the GCLC C-129T polymorphism was more frequently found in CHD cases than in controls (P < 0.01) and individuals with GCLC-129T allele had a significantly higher risk for CHD (OR = 2.38, 95% CI: 1.25 - 4.54) as compared to individuals with the -129C allele. When compared with CC homozygote, CT heterozygote had a 2.14-fold higher risk for CHD (95% CI: 1.08 - 4.24, P < 0.05) and carriers of the-129T allele (CT or TT genotype) also had a similarly 2.28-fold higher risk for CHD (95% CI: 1.16 - 4.49, P < 0.05). In contrast, the frequency of T allele of the GCLM G-23T polymorphism was lower in CHD patients than that of controls (0.174 vs. 0.264) and individuals with the GCLM-23T allele had a significantly lower risk for CHD (OR = 0.59, 95% CI: 0.42 - 0.82, P < 0.01) as compared to the -23G allele. When compared with GG homozygote, the OR of CHD for GT heterozygote was 0.71 (95% CI: 0.47 - 1.08, P > 0.05), for TT homozygote was 0.18 (95% CI: 0.06 - 0.55, P < 0.01), and for carriers of the -23T allele (GT or TT genotype) was 0.61 (95% CI: 0.42 - 0.92, P < 0.05). The GCLC C-129T polymorphism may be one of the genetic risk factor while the GCLM G-23T polymorphism may be one of the genetic protective factors for CHD in this Chinese population.